Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951028 | 1.00 | CYP2A6 (0.71) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL719619 | 0.83 | CYP2A6 (1.00) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL15823776 | 0.79 | CYP2A6 (0.46) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL6598921 | 0.79 | CYP2A6 (0.46) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL8040622 | 0.79 | CYP2A6 (0.46) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL6543324 | 0.76 | CYP2A6 (0.43) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL9754623 | 0.76 | CYP2A6 (0.65) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL16686612 | 0.75 | KDM4E (0.52) | CYP2A6KDM4EHSD17B10CYP3A4CYP2D6 | |
| SCHEMBL11769290 | 0.75 | RELA (0.55) | CYP2A6MAOAALDH1A1 | |
| SCHEMBL11769294 | 0.75 | RELA (0.55) | CYP2A6MAOAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124698-A1 | ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-19 | — | — | WO | disclosed |
| US-12020872-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | Ambient Photonics, Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3645529-B1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2023-11-22 | — | — | EP | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| EP-3621957-B1 | FUSED STILBENE DERIVATIVES AS SOLAR CELL DYES | AMBIENT PHOTONICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11664171-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | Ambient Photonics, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0776324-A1 | ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885HSD17B10 1390/4885 |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885HSD17B10 1390/4885 |
| US-12020872-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | FDFT1, SUN2, CDC73 | CYP2A6 3770/4885KDM4E 2392/4885HSD17B10 925/4885 |
| US-11664171-B2 | Stilbene and fused stilbene derivatives as solar cell dyes | SUN2, FDFT1, SIK1 | CYP2A6 3785/4885KDM4E 1702/4885HSD17B10 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.